Evidence-based, educational resources for the oncology community. Authored exclusively by a leading international faculty of oncology.
Joined October 2009
- Tweets 29,420
- Following 2,366
- Followers 6,277
- Likes 1,051
10,120 Photos and videos
Jun 12
🚨 Schedule Update 🚨
⏰ New Hours: 7:45 a.m.–3:00 p.m. EST
Join us at #BestofASCO Toronto 2026 and enter for a chance to win Ray-Ban Meta Wayfarer Smart Glasses 🎁
📍 Draw: 12:55 p.m.
#ASCO2026 #OncologyEducation
64
Jun 11
🎙️ New #MedOncNow Episode!
Dr. Shaqil Kassam sits down with Dr. Howie Lim to discuss perioperative gastric cancer, emerging evidence, and evolving treatment strategies.
Listen now. 🎧
#GastricCancer #Oncology #CancerCare #MedTwitter
42
Jun 2
🚨 Final day at #ASCO2026!
This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time.
Stay tuned for Day 4 highlights. 👇
58
Jun 1
🧬 @DrBetofMDPhD shares phase II results of OBX115, an engineered TIL therapy showing a 67% response rate in advanced melanoma, with a favorable safety profile and no need for systemic IL-2.
bit.ly/4uPLFbQ
#ASCO2026 #Melanoma
1
97
Jun 1
🧬 Dr. Paolo Ciracì presents an AI-powered histopathology biomarker that may help personalize upfront treatment decisions in metastatic colorectal cancer.
bit.ly/4obI6dl
32
Jun 1
🎗️ Dr. Ghassan Abou-Alfa shares results from EMERALD-3, where adding STRIDE TACE improved PFS to ~13 months versus 8–9 months with TACE alone in intermediate-stage HCC, supporting a potential new standard of care.
bit.ly/4usskMV
#ASCO2026
90
Jun 1
🧬 Dr. Elizabeth McDonald discusses research linking GLP-1 agonist use to a 30% lower incidence of breast cancer, highlighting a potential new avenue for cancer prevention.
bit.ly/4dGC5lo
#ASCO2026
66
Jun 1
🫁 Dr. Jamie Chaft reviews the EA5142 study, where adjuvant nivolumab showed no meaningful DFS benefit after surgery and chemotherapy, reinforcing the role of pre-operative chemoimmunotherapy in NSCLC.
bit.ly/3QaAco1
#ASCO2026
1
312
Jun 1
👁️ Dr. Marlana Orloff shares OptimUM-02 findings showing darovasertib plus crizotinib improved outcomes in metastatic uveal melanoma, addressing a major unmet need for HLA-A2 negative patients.
bit.ly/4nYgXug
#ASCO2026 #Melanoma
ASCO® 2026 Highlights: Presenter Vignette - Marlana Orloff - OncologyEducation
oncologyeducation.com 1
80
Jun 1
🎗️ Dr. Shilpa Gupta discusses the phase III MAIN-CAV trial, where adding cabozantinib to avelumab maintenance showed no clear benefit in advanced urothelial cancer, while biomarker analyses continue.
bit.ly/3PVs6PR
#ASCO2026
87
Jun 1
📊 Dr. Claudio Vernieri presents PALMARES-2 data showing selected patients with HR /HER2− advanced breast cancer may benefit from continuing first-line ET CDK4/6 inhibition beyond progression.
bit.ly/4feLNN0
#ASCO2026
1
71
Jun 1
🎗️ Dr. Lucy Gilbert shares subgroup analyses from the phase III ROSELLA trial, showing relacorilant maintained its survival benefit regardless of prior taxane exposure in platinum-resistant ovarian cancer.
bit.ly/3RxsogB
#ASCO2026
70
Jun 1
🤖 Dr. Paolo Ciracì highlights an AI-powered histopathology biomarker that may help identify which patients with metastatic colorectal cancer benefit most from upfront treatment intensification.
bit.ly/4obI6dl
#ASCO2026
1
40
Jun 1
🔬 Dr. Maggie Banys-Paluchowski presents AXSANA findings showing tumour biology—not the number of involved lymph nodes—is the strongest predictor of axillary response after neoadjuvant therapy.
bit.ly/4x1oGM7
#ASCO2026
52
Jun 1
📈 Dr. Robert Stein discusses the OPTIMA trial, demonstrating that genomic testing can identify many patients with ER /HER2− early breast cancer who may safely avoid chemotherapy.
bit.ly/4u8UD2C
#ASCO2026
1
2
126
Jun 1
🧬 Dr. Pavlos Msaouel presents findings supporting EGFR blockade in SMARCB1-deficient renal medullary carcinoma, offering a potential new treatment strategy for this rare disease.
bit.ly/4fkHIXG
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Pavlos Msaouel - OncologyEducation
oncologyeducation.com 46
Jun 1
🥗 Dr. Livia Augustin explores how Mediterranean diet, physical activity, and vitamin D may influence breast cancer recurrence and cardiometabolic health in a multicentre randomized study.
bit.ly/4u8Uv38
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Livia Augustin - OncologyEducation
oncologyeducation.com 45
Jun 1
🤝 Dr. Achim Wöckel reviews the BETTER-CARE trial, evaluating individualized, needs-based follow-up care for patients after primary breast cancer treatment.
bit.ly/4ffN5aw
#ASCO2026
28
Jun 1
🧬 @DrBetofMDPhD discusses phase II results of OBX-115, an engineered TIL therapy featuring membrane-bound IL-15, showing promising activity in advanced melanoma after immune checkpoint inhibitors.
bit.ly/4uPLFbQ
#ASCO2026
1
247
Jun 1
🎗️ @ATarhiniMDPhD reviews a phase II study of neoadjuvant ipilimumab, nivolumab, and relatlimab in high-risk resectable melanoma, highlighting the continued evolution of combination immunotherapy approaches.
bit.ly/4uf1rM9
#ASCO2026
1
2
97